Autopsy report · NCT01183884

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid for Consolidation of Second or Greater Remission of High-Risk Neuroblastoma

“Low participant accrual”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 8 years 3 months before it stopped.
• 46 participants enrolled.
• Results were posted on the registry 1 year after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

Sponsor type

University, hospital or other

Conditions

Neuroblastoma

Interventions

3F8/GM-CSF Immunotherapy Plus 13-Cis-Retinoic Acid

Participants

46

Sites

1

Countries

United States

Trials that died the same way

• Sorafenib and Letrozole, Anastrozole, or Exemestane in Treating Postmenopausal Women With Estrogen Receptor-Positive and/or Progesterone Receptor-Positive Metastatic Breast Cancer
  “lack of participant accrual” (85% match in meaning)
• A Prospective Pilot Study for the Evaluation of 18F- Fluciclovine PET/MRI in Radio-recurrent Prostate Cancer (RRPC-PET/MRI Study)
  “0 participant accrual” (83% match in meaning)
• Genomic Landscape of EGFR Mutant NSCLC Prior to Erlotinib and at the Time of Disease Progression
  “Low accrual” (82% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.